Bionano Genomics, Inc. (BNGO) News
Filter BNGO News Items
BNGO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BNGO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BNGO News From Around the Web
Below are the latest news stories about BIONANO GENOMICS INC that investors may wish to consider to help them evaluate BNGO as an investment opportunity.
Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic LeukemiaA case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was missed by karyotyping and non-informative by FISH, which they classified as a PML::RARA fusion known to occur in acute promyelocytic leukemia (APL)The researchers reported that APL, an aggressive subtype of acute myelogenous leukemia (AML), responds well to treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) classes of targeted the |
BioNano Genomics Announces $10 Million Direct OfferingThe latest update is out from BioNano Genomics ( (BNGO) ). Bionano Genomics has announced a registered direct offering involving the sale of common stock and warrants to raise approximately $10 million, with potential additional proceeds of $20 million from the exercise of warrants. The funds raised will be used for general corporate purposes, including research and development, working capital, and debt repayment, positioning the company strategically within its industry. More about BioNano Gen |
Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesSAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common st |
Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesSAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common stock equivalent) and ac |
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash RunwayProvides financial flexibility by reducing near-term debt maturities, deferring principal redemption payment, and reducing near-term cash needsSAN DIEGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a settlement agreement and amendment to its outstanding senior secured convertible debentures due May 26, 2024 (the “Amendment”). Importantly the Amendment defers the Company’s December 2024 amortization payment and reduces the payme |
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor AnalysisIn the largest study to date of bone and soft tissue tumors, OGM detected 100% of the variants found by multiple standard techniques, including karyotyping, fluorescent in-situ hybridization (FISH) & gene fusion assaysOGM was also more sensitive, including detection of diagnostic or pathogenic variants missed by karyotype in 74% (14/19) of cases that failed or were negative by karyotypingWhen OGM results and next-generation sequencing (NGS) results were combined, diagnostic and pathogenic struct |
Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy ProposalSAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on December 19, 2024, it published an open letter to stockholders in support of its proposals at its upcoming special meeting of stockholders, a copy of which is included at the end of this press release. Details of the Special Meeting of Stockholders The special meeting of stockholders will be held virtually, via live webcast at www.virtualshareholdermeeting.com/BNGO2025SM, on January 15, 2025, at 1 |
Bionano Announces Presentations at the American Society of Hematology (ASH) Annual Meeting that Underscore OGM Utility Across Blood Cancer Research and Cell & Gene TherapyThirteen scientific posters feature results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), lymphoma, and other hematological malignancy research will be presented at the conferenceThree of the 13 posters were selected to be presented in two sessions dedicated to “Acute Myeloid Leukemias (AML): Biomarkers and Molecular Markers in Diagnosis and Prognosis” and “Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal R |
Bionano Genomics Inc (BNGO) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ...Despite a significant revenue drop, Bionano Genomics Inc (BNGO) focuses on cost reduction and strategic growth initiatives to drive future success. |
Bionano Genomics (BNGO) Q3 2024 Earnings Call TranscriptBNGO earnings call for the period ending September 30, 2024. |